Luminex Corporation | Complexity Simplified.

#soliloquy-container-14815{opacity:1}#soliloquy-container-14815 li > .soliloquy-caption{display:none}#soliloquy-container-14815 li:first-child > .soliloquy-caption{display:block} xMAP COVID-19 Immunoassays

ARIES SARS-CoV-2 Assay - Now Authorized by the FDA Under EUA

Now a Medical Device Authorized for Importation or Sale for Health Canada

Clinical

Our xTAG® and MultiCode®-RTx Technologies serve a wide range of clinical applications, including infectious disease testing, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.

Research

Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.

Become a Partner

Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP Technology. Click here to start the conversation now.

Learn More

Luminex Blog

Considerations Regarding RNA Extraction Kits for SARS-CoV-2 Detection

The novel coronavirus disease (COVID-19) pandemic continues to trigger rapid development of molecular diagnostic tests around the world. Nucleic acid amplification-based tests (NAATs)—such as real-time PCR and isothermal amplification—are the gold standard in molecular diagnostic technologies that are being utilized to detect SARS-CoV-2, the COVID-19 disease-causing virus.

Continue Reading >

Visit our blog >

Workflow for the ARIES® SARS-CoV-2 Assay (EUA)

ARIES® SARS CoV 2 Assay Workflow (EUA)

Clinical Our xTAG® and MultiCode®-RTx Technologies serve a wide range of clinical applications, including infectious disease testing, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.Read More Research Our xMAP® Technology and its flexibl

Designed for use on the ARIES® System, the ARIES® SARS-CoV- 2 Assay is a moderate-complexity, sample-to-answer test that enables targeted SARS-CoV-2 detection. ARIES® consolidates the assay steps into a single workflow and reduces turnaround time with STAT and random batch testing.

Watch more videos >